Diagnostic value of DNA alteration: Loss of heterozygosity or allelic imbalance - Promising for molecular staging of prostate cancers

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Brys, Magdalena ^a   Migdalska Sȩk, Monika ^b   Pastuszak Lewandoska, Dorota ^b   Forma, Ewa ^a   Czarnecka, Karolina ^b   Domańska, Daria ^b   Nawrot, Ewa ^b   Wilkosz, Jacek ^b   Rózański, Waldemar ^b   Brzeziańska, Ewa ^b  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

LOH; Molecular markers; MSI; Prostate cancer; TRUS guided prostate biopsy

Indexed keywords

DNA; PROSTATE SPECIFIC ANTIGEN; MICROSATELLITE DNA;

ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; CANCER STAGING; CHROMOSOMAL LOCALIZATION; CHROMOSOME 11P; CHROMOSOME 12Q; CHROMOSOME 16Q; CHROMOSOME 1P; CHROMOSOME 3P; CHROMOSOME 7Q; CHROMOSOME 9P; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; TRANSRECTAL ULTRASONOGRAPHY; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; GENETICS; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; AGED; ALLELIC IMBALANCE; DNA, NEOPLASM; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84871672938     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0391-9     Document Type: Article

References (28)

1. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11:1388-413.
2. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer. 2005;41:834-45.
3. Algaba F, Epstein JI, Aldape HC, Farrow GM, Lopez-Beltran A, Maksem J, Orozco RE, Pacelli A, Pisansky TM, Trias I. Assessment of prostate carcinoma in core needle biopsy - definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer. 1996;78:376-81.
4. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-76.
5. Vinall RL, Chen JQ, Hubbard NE, Sulaimon SS, deVere White RW, Borowsky AD. Evidence for an alternate molecular progression in prostate cancer. Dis Model Mech. 2012. doi: 10.1242/dmm.008995.
6. Nwosu V, Carpten J, Trent JM, Sheridan R. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet. 2001;10:2313-8.
7. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005;41:858-87.
8. von Knobloch R, Konrad L, Barth PJ, Brandt H, Wille S, Heidenreich A, Moll R, Hofmann R. Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping. Clin Cancer Res. 2004;10:1064-73.
9. Burger M, Denzinger S, Hammerschmied CG, Tannapfel A, Obermann EC, Wieland WF, Hartmann A, Stoehr R. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med (Berl). 2006;84:833-41.
10. Czarnecka K, Pastuszak-Lewandoska D, Migdalska-Sek M, Nawrot E, Brzezinski J, Dedecjus M, Pomorski L, Brzezianska E. Aberrant methylation as a main mechanism of TSGs silencing in PTC. Front Biosci (Elite Ed). 2011;3:137-57.
11. Schwarzenbach H, Chun FK, Müller I, Seidel C, Urban K, Erbersdobler A, Huland H, Pantel K, Friedrich MG. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int. 2008;102:253-8.
12. Nupponen NN, Visakorpi T. Molecular cytogenetics of prostate cancer. Microsc Res Tech. 2000;51:456-63.
13. Brothman AR. Cytogenetic studies in prostate cancer: are we making progress? Cancer Genet Cytogenet. 1997;95:116-21.
14. Verhage BA, van Houwelingen K, Ruijter TE, Kiemeney LA, Schalken JA. Allelic imbalance in hereditary and sporadic prostate cancer. Prostate. 2003;54:50-7.
15. Karan D, Lin MF, Johansson SL, Batra SK. Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer. 2003;103:285-93.
16. Bentley L, Nakabayashi K, Monk D, Beechey C, Peters J, Birjandi Z, Khayat FE, Patel M, Preece MA, Stanier P, Scherer SW, Moore GE. The imprinted region on human chromosome 7q32 extends to the carboxypeptidase A gene cluster: an imprinted candidate for Silver-Russell syndrome. J Med Genet. 2003;40:249-56.
17. Nakanishi H, Suda T, Katoh M, Watanabe A, Igishi T, Kodani M, Matsumoto S, Nakamoto M, Shigeoka Y, Okabe T, Oshimura M, Shimizu E. Loss of imprinting of PEG1/MEST in lung cancer cell lines. Oncol Rep. 2004;12:1273-8.
18. Phillips SM, Morton DG, Lee SJ, Wallace DM, Neoptolemos JP. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br J Urol. 1994;73:390-5.
19. Oliveira C, Sousa S, Pinheiro H, Karam R, Bordeira-Carriço R, Senz J, Kaurah P, Carvalho J, Pereira R, Gusmão L, Wen X, Cipriano MA, Yokota J, Carneiro F, Huntsman D, Seruca R. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology. 2009;136:2137-48.
20. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L, Ostrander EA. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet. 1999;64:776-87.
21. Huang J, Lin Y, Li L, Qing D, Teng XM, Zhang YL, Hu X, Hu Y, Yang P, Han ZG. ARHI, as a novel suppressor of cell growth and downregulated in human hepatocellular carcinoma, could contribute to hepatocarcinogenesis. Mol Carcinog. 2009;48:130-40.
22. Weber F, Aldred MA, Morrison CD, Plass C, Frilling A, Broelsch CE, Waite KA, Eng C. Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. J Clin Endocrinol Metab. 2005;90:1149-55.
23. Murphy JA, Barrantes-Reynolds R, Kocherlakota R, Bond JP, Greenblatt MS. The CDKN2A database: integrating allelic variants with evolution, structure, function, and disease association. Hum Mutat. 2004;24:296-304.
24. Kirovski G, Stevens AP, Czech B, Dettmer K, Weiss TS, Wild P, Hartmann A, Bosserhoff AK, Oefner PJ, Hellerbrand C. Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5′-deoxy-5′-methylthioadenosine (MTA). Am J Pathol. 2011;178:1145-52.
25. Erbersdobler A, Graefen M, Wullbrand A, Hammerer P, Henke RP. Allelic losses at 8p, 10q, 11p, 13q, 16q, 17p, and 18q in prostatic carcinomas: the impact of zonal location, Gleason grade, and tumour multifocality. Prostate Cancer Prostatic Dis. 1999;2:204-10.
26. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ. p57(KIP2), a structurally distinct member of the p21(CIP1) Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995;9:650-62.
27. Satoh Y, Nakadate H, Nakagawachi T, Higashimoto K, Masaki Z, Uozumi J, Kaneko Y, Mukai T, Soejima H. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours. Br J Cancer. 2006;95:541-7.
28. Strohmeyer DM, Berger AP, Moore DH II, Bartsch G, Klocker H, Carroll PR, Loening SA, Jensen RH. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis. Prostate. 2004;59:43-58.